Viral Hepatitis Management
During hepatitis infection a high calorie diet is required along with moderate physical activity. The important step in the management of hepatitis is the intake of correct drug with correct dosage and frequency. Hepatitis A does not progress into chronic condition and hence the management requires supportive treatment such as intravenous administration of fluid and nutrition. In most cases hepatitis B results into chronic state and hence drug treatment is mandatory. The drugs used for the treatment of hepatitis B include interferon alpha, Pegylated interferon, Lamivudine, Adefovir dipivoxi, Telbivudine and Tenofovir. The drugs used in the management of hepatitis C include telaprevir, boceprevir, dasabuvir. The treatment of hepatitis D is difficult and lacks specific anti-viral drugs. The management of Hepatitis E includes bed rest along with supplementation of proper nutrition.
Related Conference of Viral Hepatitis Management
16th International Conference on Pulmonary & Respiratory Medicine
18th International Conference on Chronic Obstructive Pulmonary Disease
Viral Hepatitis Management Conference Speakers
Recommended Sessions
- Advancement in New Drug Discovery for Treatment of Hepatitis
- Critical Care and Hepatology Nursing
- Epidemiology of Hepatitis
- Hepatitis Care
- Hepatocellular Carcinoma
- Intestinal Rehabilitation
- Liver Cancer
- Liver Diseases Diagnosis
- Liver Fibrosis
- Liver Transplantation and Surgery
- Molecular Biology of Hepatitis A, B, C, D and E Viruses
- Pancreatic Diseases
- Pathophysiology of Hepatitis
- Pediatric Gastroenterology, Hepatology and Nutrition
- Pregnancy and Liver Diseases
- Recent Advances in the Viral Hepatitis C Treatment
- Types of Hepatitis
- Viral Hepatitis Management
Related Journals
Are you interested in
- Advanced Lung Imaging - PULMONOLOGY 2026 (France)
- AI in Pulmonary Diagnostics - PULMONOLOGY 2026 (France)
- COPD Innovations - PULMONOLOGY 2026 (France)
- Critical Care Pulmonology - PULMONOLOGY 2026 (France)
- Digital Respiratory Health - PULMONOLOGY 2026 (France)
- Environmental Lung Diseases - PULMONOLOGY 2026 (France)
- Interstitial Lung Diseases - PULMONOLOGY 2026 (France)
- Interventional Pulmonology - PULMONOLOGY 2026 (France)
- Lung Cancer Biomarkers - PULMONOLOGY 2026 (France)
- Mechanical Ventilation Strategies - PULMONOLOGY 2026 (France)
- Pediatric Pulmonology - PULMONOLOGY 2026 (France)
- Precision Respiratory Medicine - PULMONOLOGY 2026 (France)
- Pulmonary Fibrosis Research - PULMONOLOGY 2026 (France)
- Pulmonary Hypertension - PULMONOLOGY 2026 (France)
- Pulmonary Rehabilitation - PULMONOLOGY 2026 (France)
- Respiratory Drug Delivery - PULMONOLOGY 2026 (France)
- Respiratory Infections - PULMONOLOGY 2026 (France)
- Severe Asthma Therapies - PULMONOLOGY 2026 (France)
- Sleep & Breathing Disorders - PULMONOLOGY 2026 (France)
- Thoracic Surgery Advances - PULMONOLOGY 2026 (France)
